ethylmethylhydroxypyridine succinate

01/01/2005 - "[Effect of mexicor on oxidative stress in acute myocardial infarction]."
01/01/2011 - "We studied impact of ethylmethylhydroxypyridine succinate n the course of chronic heart failure during 3 years follow-up after myocardial infarction. "
01/01/2015 - "Cardioprotective efficacy of coenzyme Q10 (CoQ10, ubidecarenone) and mexicor were evaluated on the 21st day of experimental myocardial infarction in Wistar rats. "
01/01/2015 - "[COMPARATIVE CARDIOPROTECTIVE EFFICACY OF COENZYME Q10 AND MEXICOR IN EXPERIMENTAL MODEL OF MYOCARDIAL INFARCTION IN RATS]."
01/01/2005 - "Mexicor (5% solution and capsules) was used in 40 of 80 conventionally treated patients with acute myocardial infarction. "

01/01/2013 - "Mexicor promoted combined hypolipidemic effect, reduced the degree of insulin resistance, improved hepatic metabolism, and lowered cardiovascular risks in patients with CHD and DM2."
01/01/2006 - "To study mexicor effects on functional activity of beta-cells, insulin resistance, lipid metabolism and lipid peroxidation in patients with diabetes mellitus (DM) type 2. Twenty patients with DM type 2 participated in a double blind randomized trial of mexicor vs placebo. "
01/01/2006 - "Mexicor in therapy of DM type 2 improves carbohydrate and lipid metabolism, lipid peroxidation, activates antioxidant defence enzymes, functional activity of beta-cells, reduces insulin resistance."
01/01/2006 - "Mexicor significantly improved compensation of carbohydrate metabolism by glucose and glycosylated hemoglobin in the blood, insulin resistance value, lipid metabolism and lipid peroxidation in activation of antioxidant enzymes. "

01/01/2013 - "[Additional advantages of mexicor used in combined therapy of coronary heat disease and diabetes mellitus of 2nd type]."
01/01/2020 - "[The efficacy of ethylmethylhydroxypyridine succinate in patients with cerebrovascular pathology complicated with diabetes mellitus and metabolic syndrome]."
01/01/2006 - "To study mexicor effects on functional activity of beta-cells, insulin resistance, lipid metabolism and lipid peroxidation in patients with diabetes mellitus (DM) type 2. Twenty patients with DM type 2 participated in a double blind randomized trial of mexicor vs placebo. "
01/01/2013 - "This open prospective randomized 16-week study of combined therapy of coronary heat disease (CHD) and and diabetes mellitus of 2nd type (DM2) with secondary non-alcoholic fatty liver disease (NAFLD) including mexicor was designed to estimate structural and functional liver characteristics. "

01/01/2022 - "[Results of clinical studies of the efficacy and safety of the use of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia]."
01/01/2020 - "[Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia]."
01/01/2018 - "In particular, the inclusion of mexicor in the treatment of patients with chronic pulmonary heart increases the efficacy of treatment of the main and associated diseases (chronic cerebral ischemia, cardiac insufficiency and arrhythmia). "
01/01/2023 - "To evaluate an effect of ethylmethylhydroxypyridine succinate and ethylmethylhydroxypyridine malate on changes in mitochondrial function under experimental focal cerebral ischemia. "
01/01/2023 - "[An effect of ethylmethylhydroxypyridine succinate and ethylmethylhydroxypyridine malate on changes in mitochondrial function under conditions of focal cerebral ischemia]."

01/01/2004 - "To study efficacy of cytoprotector mexicor in patients with unstable angina (UA), acute myocardial infarction (MI), hypertensive crises (HC) in combined therapy with conventional drugs. "